InflaRx NV
IFRX
Company Profile
Business description
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
Contact
Winzerlaer Strasse 2
Jena07745
DEUT: +49 3641508180
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
74
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,365.70 | 24.70 | 0.30% |
| CAC 40 | 7,593.87 | 38.00 | 0.50% |
| DAX 40 | 22,496.98 | 71.15 | 0.32% |
| Dow JONES (US) | 40,939.80 | 270.44 | 0.66% |
| FTSE 100 | 8,496.80 | 1.95 | 0.02% |
| HKSE | 22,119.41 | 111.30 | 0.51% |
| NASDAQ | 17,842.76 | 396.42 | 2.27% |
| Nikkei 225 | 36,452.30 | 406.92 | 1.13% |
| NZX 50 Index | 12,148.60 | 245.29 | 2.06% |
| S&P 500 | 5,640.40 | 71.34 | 1.28% |
| S&P/ASX 200 | 8,145.60 | 19.40 | 0.24% |
| SSE Composite Index | 3,279.03 | 7.62 | -0.23% |